Biotech development

Q&A: Blackstone Life Sciences head on drug R&D in Asia

Blackstone Life Sciences head Nicholas Galakatos talks regulation and the drug R&D process, and explains how investors can avoid mistakes in the pharmaceutical gold rush.

An ageing population in Asia has expanded the scope for pharmaceutical companies. And countries, in turn, are using regulation to speed up the drug development process as they embrace a dynamic life science market.

This demographic shift has attracted the attention of investors outside the region. In an exclusive interview with FinanceAsia, Nicholas Galakatos, head of the Blackstone Life Sciences business, shares his views on the development of the life science sector in Asia.

Galakatos joined Blackstone as part of its acquisition of Clarus in December last year, indeed he had co-founded Clarus in 2005. Galakatos has more than 30 years of industry...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222